NasdaqCM:OTLKBiotechs
Outlook Therapeutics (OTLK) Is Down 36.3% After First FDA‑Approved Ophthalmic Bevacizumab Win - What's Changed
Outlook Therapeutics recently received U.S. FDA approval for LYTENAVA (bevacizumab‑vikg) to treat neovascular (wet) age-related macular degeneration, making it the first and only FDA‑approved ophthalmic bevacizumab in the U.S. retina market.
This approval, which the company believes qualifies LYTENAVA for 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act, positions Outlook Therapeutics in an approximately US$8.50 billion annual U.S. anti‑VEGF...